Form 4: Passage Bio Director Derrell Porter Granted Significant Stock Options

Passage Bio, Inc. Director Derrell Porter was granted 201,857 stock options with an exercise price of $0.3598, vesting over one year or by the 2026 Annual Meeting.

Summary

• Derrell Porter, a Director of Passage BIO, Inc. (PASG), was granted 201,857 stock options.
• The options have an exercise price of $0.3598 per share.
• These options vest in full on the earlier of the one-year anniversary of the grant date (May 28, 2026) or the date of the issuer's 2026 Annual Meeting of stockholders.
• Vesting is contingent upon Mr. Porter's continuous service to the issuer.
• The options expire on May 28, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a neutral to slightly positive event, as it aligns director incentives with shareholder value. It's a standard compensation practice and doesn't indicate significant operational news, but it does show continued commitment from a board member.

Positives

• The grant of stock options aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases above the exercise price.
• The vesting schedule encourages long-term commitment and continuous service from a key director.

Negatives

• The issuance of new stock options could lead to potential dilution for existing shareholders if exercised, although this is a standard compensation practice.

Industry Context

This is a standard compensation practice for directors in publicly traded companies, particularly in the biotechnology sector where attracting and retaining experienced leadership is crucial. Equity grants like stock options are common incentives to align director interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of equity compensation across various industries, including biotechnology.
• The vesting period (one year or next annual meeting) is typical for director grants, aiming to incentivize continued service.
• The exercise price of $0.3598 is likely the closing price of PASG common stock on the grant date, which is standard practice for "at-the-money" option grants.
• Comparable companies in the biotechnology sector, such as those with similar market capitalization or development stages, frequently use similar equity compensation structures for their non-employee directors.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also improved alignment of director incentives with shareholder value.

Next Steps

• The stock options will vest on the earlier of May 28, 2026, or the date of Passage Bio's 2026 Annual Meeting.
• Derrell Porter must maintain continuous service to Passage Bio for the options to vest.

Key Dates

Recommendation

Keywords

Passage Bio, PASG, Derrell Porter, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Biotechnology, Pharmaceuticals